Gentel Biosciences launched the Gentel Proteomics Multi-System this week.
According to the company, the system provides "'scan-to-analysis functionality for multiplex immunoassays, lysate, and antigen arrays," as well as Western blots, ELISAs, and tissue imaging.
The system includes a high-resolution scanner and a laptop computer configured with image-capture and -analysis software "capable of data extraction and quantitation," the company said. It also supports the use of Gentel's APIX chromegenic reagents and slides and non-fluorescent proteomics products from other vendors.
Thermo Fisher Scientific this week launched Thermo Scientific Dylight 680B Dyes for directly labeling proteins and other biomolecules.
The dye exhibits fluorescence intensity up to 10 times greater than similar dyes and is useful for a number of applications including protein arrays, in vivo imaging, and ELISA analyses, Thermo Fisher said in a statement. The dyes are available in amine and sulfhydryl-reactive chemistries.
In an update, Vermillion this week said that it and Quest Diagnostics are on track to launch the OVA1 ovarian cancer test in March.
The company had originally said the diagnostic would be launched by the end of 2009 but more recently targeted the first quarter of 2010.
The test, comprised of five proteins, is intended to help clinicians decide whether a pelvic mass is benign or malignant before surgery. The US Food and Drug Administration gave the test 510(k) clearance in September [See PM 09/17/09].
Biotage this week introduced the Syro Wave, a microwave and parallel peptide synthesizer.
Bioteag said that the system is the only one that offers both microwave and parallel peptide synthesis capabilities. The system is the result of a joint project between Biotage and MultiSynTech, and combines the performance of the MultiSynTech robotic synthesizer with Biotage's microwave technology, Biotage said.